You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The collaborators hope to establish new models of human disease using patient-derived stem cells, with support from Bloomberg Philanthropies.
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
Evotec will gain non-exclusive rights to Ncardia IP, including a broad panel of stem cell-derived cell lines for use in drug target discovery and testing.
The companies will offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.
Eleven new studies from the NHLBI NextGen Consortium show different uses for iPSCs to study polygenetic diseases across various systems in the human body.
The deal gives Axiogenesis access to IP that will allow it to commercialize stem cell-derived assays and disease models for use in drug discovery.
NEW YORK (GenomeWeb News) – Cambridge, UK-based Definigen said today that it has raised a total of £2.3 million ($3.8 million) in a Series A round of funding.
Epistem plans to use novel preclinical models for cutaneous wound healing developed by a University of Manchester scientist under a partnership that is supported by a UK government business development program.
ILS and Stemina Biomarker Discovery today announced they will work together to advance Stemina's stem cell-based toxicology testing platform.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.
CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.
Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.
In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.